10 Best Gene Editing Stocks To Buy

Published on October 14, 2022 at 9:49 am by Hamna Asim in Hedge Funds, News

In this article, we discuss 10 best gene editing stocks to buy. If you want to see more stocks in this selection, check out 5 Best Gene Editing Stocks To Buy.

A report by The Wall Street Journal dated September 16 suggests that Intellia Therapeutics, Inc. (NASDAQ:NTLA) revealed positive early-stage trial results for its CRISPR gene-editing treatments, which is the latest indication that the trailblazing technology could generate commercially viable drugs in the near future.

There have been many new developments in the gene editing space. A group of researchers from Northwestern University have developed a unique platform for gene editing that could be utilized in the future application of nearly limitless CRISPR-based therapeutics. The team found a solution to transform the Cas-9 protein into a spherical nucleic acid (SNA) and fill it with complex components as required to approach a huge range of tissue and cell types, as well as the intracellular compartments necessary for gene editing. This was previously a limitation of CRISPR. The new study improves upon a 25-year study led by nanotechnology pioneer, Chad A. Mirkin.

Similarly, the CRISPR innovator Feng Zhang is launching another aspiring gene-editing startup, funded by nearly $200 million from some of biotech’s most prominent investors. The startup, named Aera Therapeutics, aims to overcome a consistent gene-editing constraint – delivering genetic goods, including CRISPR, into multiple different organs. To benefit from the boom in the gene editing space, investors could check out some notable gene editing players in the market including AbbVie Inc. (NYSE:ABBV), Agilent Technologies, Inc. (NYSE:A), and CRISPR Therapeutics AG (NASDAQ:CRSP).

Our Methodology

We selected the following gene editing stocks based on growth fundamentals, ongoing and pipeline projects, positive analyst coverage, and strong hedge fund sentiment as of June 2022. We have arranged the list of the best gene editing stocks according to the number of hedge fund holders in each firm, tracked by Insider Monkey as of the second quarter of 2022.

Photo by CDC on Unsplash

Best Gene Editing Stocks To Buy

10. Allogene Therapeutics, Inc. (NASDAQ:ALLO)

Number of Hedge Fund Holders: 17

Allogene Therapeutics, Inc. (NASDAQ:ALLO) is a California-based clinical stage immuno-oncology company that develops and commercializes genetically engineered allogeneic T cell therapies for cancer treatment. On October 6, Allogene Therapeutics, Inc. (NASDAQ:ALLO) announced that it has started the phase 2 ALPHA2 trial of ALLO-501A, an allogeneic chimeric antigen receptor T cell (AlloCAR T) therapy for relapsed/refractory large B-cell lymphoma. The company is also in the process of initiating the phase 2 EXPAND trial for ALLO-647, an anti-CD52 monoclonal antibody, which would be utilized with ALLO-501A and other AlloCAR T therapies to enhance clinical results.

On September 22, B. Riley analyst Kalpit Patel maintained a Buy rating on Allogene Therapeutics, Inc. (NASDAQ:ALLO) but lowered the price target on the shares to $18 from $21 after the company revealed that Servier has sent a notice of termination of its participation in the development of all licensed CD19-targeting products, including UCART19, ALLO-501, and ALLO-501A. Servier’s discontinuation allows Allogene Therapeutics, Inc. (NASDAQ:ALLO) the right to gain a license for CD19 products outside the U.S. territories, the analyst told investors in a research note.

According to Insider Monkey’s data, 17 hedge funds were bullish on Allogene Therapeutics, Inc. (NASDAQ:ALLO) at the end of Q2 2022, compared to 20 funds in the prior quarter. Woodline Partners is the leading position holder in the company, with 5.85 million shares worth $66.80 million.

Like AbbVie Inc. (NYSE:ABBV), Agilent Technologies, Inc. (NYSE:A), and CRISPR Therapeutics AG (NASDAQ:CRSP), Allogene Therapeutics, Inc. (NASDAQ:ALLO) is one of the best gene editing stocks to invest in.

9. Beam Therapeutics Inc. (NASDAQ:BEAM)

Number of Hedge Fund Holders: 17

Next on our list of the best gene editing stocks is Beam Therapeutics Inc. (NASDAQ:BEAM), which was incorporated in 2017 and is based in Cambridge, Massachusetts. It is a biotechnology firm that develops precision genetic medicines for patients suffering from serious diseases in the United States. Some of its therapeutic focus areas include sickle cell disease, beta thalassemia, T-cell acute lymphoblastic leukemia, ocular diseases, and liver, muscle, and central nervous system disorders.

Beam Therapeutics Inc. (NASDAQ:BEAM) announced on September 19 new preclinical data indicating the potential of the company’s multiplex base editing approach to both reduce viral markers, including hepatitis B surface antigen expression, and prevent viral rebound of hepatitis B virus in ‘in vivo’ models. The findings show that base editing has the capacity to permanently inactivate cccDNA and integrated HBV DNA by developing mutations that stop HBV replication and suppress viral protein expression.

On August 10, Barclays analyst Gena Wang raised the price target on Beam Therapeutics Inc. (NASDAQ:BEAM) to $60 from $38 and maintained an Equal Weight rating on the shares following the Q2 results.

According to Insider Monkey’s data, 17 hedge funds were long Beam Therapeutics Inc. (NASDAQ:BEAM) at the end of the second quarter of 2022, compared to 20 funds in the prior quarter. Cathie Wood’s ARK Investment Management is the largest stakeholder of the company, with nearly 8.80 million shares worth $309.30 million.

Here is what Baron Health Care Fund has to say about Beam Therapeutics Inc. (NASDAQ:BEAM) in their Q1 2021 investor letter:

“Beam Therapeutics Inc. is a biotechnology company pioneering a novel technology called base editing, which allows for individual base pairs (the letters of DNA) to be modified. Shares fell along with other biotechnology stocks driven by a sudden rise in treasury yields. Early stage biotechnology stocks are particularly sensitive to interest rates because their cash flows are further in the future. We believe we are entering into a phase of significant advancement for the gene editing field that will eventually lead to curative therapies, and we think Beam has a unique platform technology.”

8. Editas Medicine, Inc. (NASDAQ:EDIT)

Number of Hedge Fund Holders: 18

Editas Medicine, Inc. (NASDAQ:EDIT) is a Massachusetts-based clinical stage genome editing company, specializing in the development of transformative genomic medicines to treat multiple serious diseases. It operates a proprietary gene editing platform based on CRISPR technology. The company reported a Q2 2022 revenue of $6.36 million, climbing 1573.7% on a year-over-year basis, beating market estimates by $2.07 million. It is one of the best gene editing stocks to invest in.

On September 29, BofA analyst Greg Harrison initiated coverage of Editas Medicine, Inc. (NASDAQ:EDIT) with a Neutral rating and an $18 price target. The analyst said the company posted “mixed” initial clinical data from its key program, EDIT-101 in LCA10, and he sees strong competition in hemoglobinopathies for EDIT-301. Data so far has been limited, and with the latest failures from peers, investors are wary. However, with no treatments available, the analyst thinks “the bar is low for approval” and sees a high penetration for EDIT-101 in new patients with peak sales of $295 million.

According to Insider Monkey’s data, 18 hedge funds held stakes worth nearly $65 million in Editas Medicine, Inc. (NASDAQ:EDIT) at the end of June 2022, compared to 18 in the prior quarter worth $98.2 million. Ken Griffin’s Citadel Investment Group is the leading position holder in the company, with 1.25 million shares worth about $15 million.

7. Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

Number of Hedge Fund Holders: 19

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) is headquartered in Brisbane, California, operating as a clinical-stage biotechnology company, focusing on the development of genomic medicines using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. Sangamo Therapeutics, Inc. (NASDAQ:SGMO) is one of the best gene editing stocks to buy now.

On October 11, Sangamo Therapeutics, Inc. (NASDAQ:SGMO) announced updated preliminary results from the Phase 1/2 STAAR clinical study evaluating ST-920, a wholly owned gene therapy product candidate for the treatment of Fabry disease. The data indicates that the treatment continued to be generally well tolerated, with no treatment-related serious risks found in the trial candidates. Sangamo Therapeutics, Inc. (NASDAQ:SGMO) is planning for a potential Phase 3 clinical trial.

Among the hedge funds tracked by Insider Monkey, 19 funds reported owning stakes worth $48.3 million in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) at the end of Q2 2022, compared to 18 funds in the prior quarter worth $37.8 million. Chris Rokos’ Rokos Capital Management is the leading stakeholder of the company, with 3 million shares worth $12.5 million.

Here is what Wasatch Ultra Growth Fund has to say about Sangamo Therapeutics, Inc. (NASDAQ:SGMO) in its Q1 2021 investor letter:

“Another weak stock in the Fund was Sangamo Therapeutics, Inc. (SGMO). Some investors may have been spooked by the resignation of Sangamo’s chief financial officer (CFO) after a tenure of less than one year. After conducting our own research, which included a conversation with the departing CFO, we believe the move was purely for personal reasons. Sangamo specializes in the treatment and cure of single-gene disorders. We remain optimistic about its future prospects, current partnerships and development pipeline— which includes gene therapy, in-vivo gene editing and ex-vivo genome medicine. (Current and future holdings are subject to risk.)”

6. Caribou Biosciences, Inc. (NASDAQ:CRBU)

Number of Hedge Fund Holders: 20

Caribou Biosciences, Inc. (NASDAQ:CRBU) is a California-based clinical-stage biopharmaceutical company that engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. In the beginning of September, Caribou Biosciences, Inc. (NASDAQ:CRBU)’s follicular lymphoma treatment was granted orphan designation by the FDA.

On August 29, Citi analyst Yigal Nochomovitz maintained a Buy recommendation on Caribou Biosciences, Inc. (NASDAQ:CRBU) but lowered the price target on the shares to $38 from $39. The analyst updated the company’s model after the Q2 results.

According to Insider Monkey’s second quarter database, 20 hedge funds were long Caribou Biosciences, Inc. (NASDAQ:CRBU), compared to 22 funds in the last quarter. Partner Fund Management is the biggest stakeholder of the company, with 6 million shares worth $32.5 million.

For exposure to the gene editing space, smart investors pile into Caribou Biosciences, Inc. (NASDAQ:CRBU), as well as AbbVie Inc. (NYSE:ABBV), Agilent Technologies, Inc. (NYSE:A), and CRISPR Therapeutics AG (NASDAQ:CRSP).

Click to continue reading and see 5 Best Gene Editing Stocks To Buy.

A New Dawn is Coming to U.S. Stocks

Published on May 2, 2024 at by Insider Monkey Staff

I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.

We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…

Should I put my money in Artificial Intelligence?

Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.

Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…

But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.

That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…

And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.

He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.

Click to continue reading…

Insider Monkey Ads

AI Fire Sale: Insider Monkey’s #1 AI Stock Pick Is On A Steep Discount

Published on May 1, 2024 at by Inan Dogan, PhD

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

The whispers are turning into roars.

Artificial intelligence isn’t science fiction anymore.

It’s the revolution reshaping every industry on the planet.

From driverless cars to medical breakthroughs, AI is on the cusp of a global explosion, and savvy investors stand to reap the rewards.

Here’s why this is the prime moment to jump on the AI bandwagon:

Exponential Growth on the Horizon: Forget linear growth – AI is poised for a hockey stick trajectory.

Imagine every sector, from healthcare to finance, infused with superhuman intelligence.

We’re talking disease prediction, hyper-personalized marketing, and automated logistics that streamline everything.

This isn’t a maybe – it’s an inevitability.

Early investors will be the ones positioned to ride the wave of this technological tsunami.

Ground Floor Opportunity: Remember the early days of the internet?

Those who saw the potential of tech giants back then are sitting pretty today.

AI is at a similar inflection point.

We’re not talking about established players – we’re talking about nimble startups with groundbreaking ideas and the potential to become the next Google or Amazon.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 10,000% Return: This AI Stock is a Diamond in the Rough (But Our Help is Key!)

The AI revolution is upon us, and savvy investors stand to make a fortune.

But with so many choices, how do you find the hidden gem – the company poised for explosive growth?

That’s where our expertise comes in.

We’ve got the answer, but there’s a twist…

Imagine an AI company so groundbreaking, so far ahead of the curve, that even if its stock price quadrupled today, it would still be considered ridiculously cheap.

That’s the potential you’re looking at. This isn’t just about a decent return – we’re talking about a 10,000% gain over the next decade!

Our research team has identified a hidden gem – an AI company with cutting-edge technology, massive potential, and a current stock price that screams opportunity.

This company boasts the most advanced technology in the AI sector, putting them leagues ahead of competitors.

It’s like having a race car on a go-kart track.

They have a strong possibility of cornering entire markets, becoming the undisputed leader in their field.

Here’s the catch (it’s a good one): To uncover this sleeping giant, you’ll need our exclusive intel.

We want to make sure none of our valued readers miss out on this groundbreaking opportunity!

That’s why we’re slashing the price of our Premium Readership Newsletter by a whopping 75%.

For a ridiculously low price of just $24, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single restaurant meal!

Here’s why this is a deal you can’t afford to pass up:

The Name of the Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.
Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.
Lifetime Money-Back Guarantee: If you’re not absolutely satisfied with our service, we’ll provide a full refund ANYTIME, no questions asked.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

Head over to our website and subscribe to our Premium Readership Newsletter for just $24.
Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.
Sit back, relax, and know that you’re backed by our ironclad lifetime money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Subscribe Now!

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Log In

Sign Up